JP5808408B2 - フタラジノンケトン誘導体、その製造法および医薬用途 - Google Patents
フタラジノンケトン誘導体、その製造法および医薬用途 Download PDFInfo
- Publication number
- JP5808408B2 JP5808408B2 JP2013523468A JP2013523468A JP5808408B2 JP 5808408 B2 JP5808408 B2 JP 5808408B2 JP 2013523468 A JP2013523468 A JP 2013523468A JP 2013523468 A JP2013523468 A JP 2013523468A JP 5808408 B2 JP5808408 B2 JP 5808408B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pyrazine
- mmol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1C=Cc([o]cc2)c2C=C1 Chemical compound C*1C=Cc([o]cc2)c2C=C1 0.000 description 8
- PAXLJNGPFJEKQX-UHFFFAOYSA-N OC(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O Chemical compound OC(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O PAXLJNGPFJEKQX-UHFFFAOYSA-N 0.000 description 2
- YZBDXDPBLIQCJY-UHFFFAOYSA-N C1NCc2ccc[n]2C1 Chemical compound C1NCc2ccc[n]2C1 YZBDXDPBLIQCJY-UHFFFAOYSA-N 0.000 description 1
- UANMXKOQPAYQTK-SREVYHEPSA-N CC(C)(C=C)/C=C\c1c(C)[s]cn1 Chemical compound CC(C)(C=C)/C=C\c1c(C)[s]cn1 UANMXKOQPAYQTK-SREVYHEPSA-N 0.000 description 1
- HBYQLDXFOSICGN-UHFFFAOYSA-N CC(c1nnc(C2)[n]1CCN2C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O)(F)F Chemical compound CC(c1nnc(C2)[n]1CCN2C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O)(F)F HBYQLDXFOSICGN-UHFFFAOYSA-N 0.000 description 1
- CAXQEPUTRSXRFF-UHFFFAOYSA-N CC1(C)C=Cc([nH]nc2)c2C=C1 Chemical compound CC1(C)C=Cc([nH]nc2)c2C=C1 CAXQEPUTRSXRFF-UHFFFAOYSA-N 0.000 description 1
- MIKQYOLBQDHXOC-ATVHPVEESA-N CCC(C)C/C=N\C1=C(C)C=CC(C)(C)C=C1 Chemical compound CCC(C)C/C=N\C1=C(C)C=CC(C)(C)C=C1 MIKQYOLBQDHXOC-ATVHPVEESA-N 0.000 description 1
- UOBUHTDALANGAI-UHFFFAOYSA-N COC(c1c(CNCC2)[n]2c(C(F)(F)[I]=C)n1)=O Chemical compound COC(c1c(CNCC2)[n]2c(C(F)(F)[I]=C)n1)=O UOBUHTDALANGAI-UHFFFAOYSA-N 0.000 description 1
- FMTDZGCPYKWMPT-UHFFFAOYSA-N FC(c1nnc2[n]1CCNC2)(F)F Chemical compound FC(c1nnc2[n]1CCNC2)(F)F FMTDZGCPYKWMPT-UHFFFAOYSA-N 0.000 description 1
- WSRPPCUPGXRMRW-UHFFFAOYSA-N N=C(C(F)(F)F)N(CCN(C1)C(c2cc(CC(c3ccccc33)=NNC3=O)ccc2F)=O)C1=N Chemical compound N=C(C(F)(F)F)N(CCN(C1)C(c2cc(CC(c3ccccc33)=NNC3=O)ccc2F)=O)C1=N WSRPPCUPGXRMRW-UHFFFAOYSA-N 0.000 description 1
- DYWUYPWTHFULMZ-UHFFFAOYSA-N NC(c1c(CN(CC2)C(c(cc(CC(c3ccccc33)=NNC3=O)cc3)c3F)=O)[n]2c(C(F)(F)F)n1)=O Chemical compound NC(c1c(CN(CC2)C(c(cc(CC(c3ccccc33)=NNC3=O)cc3)c3F)=O)[n]2c(C(F)(F)F)n1)=O DYWUYPWTHFULMZ-UHFFFAOYSA-N 0.000 description 1
- ZWATXLDMXAWLLA-UHFFFAOYSA-N O=C(c1cc(CC(C2=C3C=CC=CC2)=NNC3=O)ccc1F)N1Cc2ccc[n]2CC1 Chemical compound O=C(c1cc(CC(C2=C3C=CC=CC2)=NNC3=O)ccc1F)N1Cc2ccc[n]2CC1 ZWATXLDMXAWLLA-UHFFFAOYSA-N 0.000 description 1
- JPYXQNYTOSHIAC-UHFFFAOYSA-N O=C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)N1Cc2ccc[n]2CC1 Chemical compound O=C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)N1Cc2ccc[n]2CC1 JPYXQNYTOSHIAC-UHFFFAOYSA-N 0.000 description 1
- XUCMOPZFOKSXAA-UHFFFAOYSA-N O=C1OC2=CCCC=C2C=C1 Chemical compound O=C1OC2=CCCC=C2C=C1 XUCMOPZFOKSXAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010248307.5 | 2010-08-09 | ||
| CN2010102483075A CN102372716A (zh) | 2010-08-09 | 2010-08-09 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2011/001223 WO2012019427A1 (zh) | 2010-08-09 | 2011-07-26 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535491A JP2013535491A (ja) | 2013-09-12 |
| JP2013535491A5 JP2013535491A5 (enExample) | 2014-07-24 |
| JP5808408B2 true JP5808408B2 (ja) | 2015-11-10 |
Family
ID=45567315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523468A Active JP5808408B2 (ja) | 2010-08-09 | 2011-07-26 | フタラジノンケトン誘導体、その製造法および医薬用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9273052B2 (enExample) |
| EP (1) | EP2604610B1 (enExample) |
| JP (1) | JP5808408B2 (enExample) |
| KR (1) | KR101829940B1 (enExample) |
| CN (2) | CN102372716A (enExample) |
| AU (1) | AU2011288876B2 (enExample) |
| BR (1) | BR112013002220B1 (enExample) |
| CA (1) | CA2806324C (enExample) |
| ES (1) | ES2582315T3 (enExample) |
| HU (1) | HUE029275T2 (enExample) |
| PL (1) | PL2604610T3 (enExample) |
| PT (1) | PT2604610T (enExample) |
| RU (1) | RU2564527C2 (enExample) |
| UA (1) | UA111161C2 (enExample) |
| WO (1) | WO2012019427A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| WO2014102817A1 (en) | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| RU2750151C2 (ru) | 2015-11-20 | 2021-06-22 | Форма Терапьютикс, Инк. | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 |
| CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| WO2017101796A1 (zh) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| TWI771344B (zh) * | 2016-12-01 | 2022-07-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| CN110475779A (zh) | 2017-04-12 | 2019-11-19 | 豪夫迈·罗氏有限公司 | 标记含醛靶分子的方法 |
| MX2020002046A (es) * | 2017-08-24 | 2020-09-17 | Jiangsu Hengrui Medicine Co | Forma cristalina del inhibidor de parp-1 y método de preparación de ésta. |
| BR112020010435A2 (pt) * | 2017-12-06 | 2020-11-24 | Jiangsu Hengrui Medicine Co., Ltd. | uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia |
| WO2019137358A1 (zh) | 2018-01-09 | 2019-07-18 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂及其中间体的制备方法 |
| AU2019212093B2 (en) | 2018-01-26 | 2024-05-30 | Recordati Industria Chimica E Farmaceutica S.P.A | Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mGlu5 receptors |
| WO2019169156A1 (en) * | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| BR112020019824A2 (pt) * | 2018-03-29 | 2021-01-05 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| CN112584836A (zh) * | 2018-10-22 | 2021-03-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 |
| KR102912737B1 (ko) * | 2018-11-16 | 2026-01-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Parp 억제제를 포함하는 약학 조성물 |
| TW202110448A (zh) * | 2019-05-28 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CA3176219A1 (en) | 2020-04-21 | 2021-10-28 | Kunhee LEE | Crystalline forms of phthalazinone compound |
| JP7626783B2 (ja) | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| CN111732594B (zh) * | 2020-08-18 | 2022-03-04 | 苏州富士莱医药股份有限公司 | 一种氟唑帕利的制备方法 |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| AU2021355480B2 (en) | 2020-10-02 | 2026-03-05 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4349836A4 (en) * | 2021-05-24 | 2024-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS |
| US20240317762A1 (en) * | 2021-07-16 | 2024-09-26 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| CA3226796A1 (en) * | 2021-07-29 | 2023-02-02 | Xiaoxia Yan | Novel parp7 inhibitor and use thereof |
| CN115650988B (zh) * | 2022-10-27 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂的制备方法 |
| WO2024109871A1 (zh) * | 2022-11-23 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| WO2024188265A1 (zh) * | 2023-03-13 | 2024-09-19 | 江苏豪森药业集团有限公司 | 哌啶烯类化合物在制备治疗癌症的药物中的应用 |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| PL372171A1 (en) * | 2002-02-19 | 2005-07-11 | Ono Pharmaceutical Co, Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| AR043443A1 (es) | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
| BRPI0408284B8 (pt) * | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| MX2007002318A (es) | 2004-08-26 | 2007-04-17 | Kudos Pharm Ltd | Derivados de ftalazinona substituidos con 4-heteroarilmetilo. |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| DK2120579T3 (da) | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| WO2009025784A1 (en) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| JP2011509962A (ja) | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
-
2010
- 2010-08-09 CN CN2010102483075A patent/CN102372716A/zh active Pending
-
2011
- 2011-07-26 KR KR1020137003185A patent/KR101829940B1/ko active Active
- 2011-07-26 HU HUE11815986A patent/HUE029275T2/en unknown
- 2011-07-26 BR BR112013002220-5A patent/BR112013002220B1/pt active IP Right Grant
- 2011-07-26 WO PCT/CN2011/001223 patent/WO2012019427A1/zh not_active Ceased
- 2011-07-26 AU AU2011288876A patent/AU2011288876B2/en active Active
- 2011-07-26 UA UAA201301524A patent/UA111161C2/uk unknown
- 2011-07-26 EP EP11815986.2A patent/EP2604610B1/en active Active
- 2011-07-26 PT PT118159862T patent/PT2604610T/pt unknown
- 2011-07-26 US US13/811,957 patent/US9273052B2/en active Active
- 2011-07-26 JP JP2013523468A patent/JP5808408B2/ja active Active
- 2011-07-26 ES ES11815986.2T patent/ES2582315T3/es active Active
- 2011-07-26 CA CA2806324A patent/CA2806324C/en active Active
- 2011-07-26 CN CN201180003990.9A patent/CN102686591B/zh active Active
- 2011-07-26 RU RU2013106754/04A patent/RU2564527C2/ru active
- 2011-07-26 PL PL11815986.2T patent/PL2604610T3/pl unknown
-
2016
- 2016-02-05 US US15/016,986 patent/US9566277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2604610A4 (en) | 2013-12-25 |
| EP2604610A1 (en) | 2013-06-19 |
| CA2806324A1 (en) | 2012-02-16 |
| KR20130110149A (ko) | 2013-10-08 |
| CN102686591B (zh) | 2014-03-19 |
| BR112013002220B1 (pt) | 2021-09-21 |
| US9273052B2 (en) | 2016-03-01 |
| PT2604610T (pt) | 2016-07-13 |
| WO2012019427A1 (zh) | 2012-02-16 |
| HK1174030A1 (en) | 2013-05-31 |
| AU2011288876A2 (en) | 2013-02-21 |
| US20160151367A1 (en) | 2016-06-02 |
| US9566277B2 (en) | 2017-02-14 |
| CN102686591A (zh) | 2012-09-19 |
| AU2011288876B2 (en) | 2014-08-21 |
| JP2013535491A (ja) | 2013-09-12 |
| ES2582315T3 (es) | 2016-09-12 |
| RU2564527C2 (ru) | 2015-10-10 |
| RU2013106754A (ru) | 2014-09-20 |
| US20130131068A1 (en) | 2013-05-23 |
| HUE029275T2 (en) | 2017-02-28 |
| EP2604610B1 (en) | 2016-05-11 |
| UA111161C2 (uk) | 2016-04-11 |
| WO2012019427A8 (zh) | 2012-05-10 |
| CN102372716A (zh) | 2012-03-14 |
| AU2011288876A1 (en) | 2013-01-31 |
| PL2604610T3 (pl) | 2016-11-30 |
| CA2806324C (en) | 2019-02-19 |
| KR101829940B1 (ko) | 2018-02-19 |
| BR112013002220A2 (pt) | 2016-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5808408B2 (ja) | フタラジノンケトン誘導体、その製造法および医薬用途 | |
| ES2590682T3 (es) | Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos | |
| KR102599788B1 (ko) | 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클 | |
| CN102762549B (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| CN116514846A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
| JP2019522055A (ja) | Ｆｇｆｒ阻害剤として使用される複素環式化合物 | |
| CN106187915A (zh) | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 | |
| ES2927959T3 (es) | Compuestos de imidazol heterocíclicos, composiciones farmacéuticas de los mismos, método de preparación de los mismos y uso de los mismos | |
| CN115485281B (zh) | 一种fgfr及其突变抑制剂,其制备方法和应用 | |
| CN109761986B (zh) | 三并环类衍生物抑制剂、其制备方法和应用 | |
| CN118684666A (zh) | Kif18a抑制剂及其用途 | |
| CN104774188B (zh) | 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用 | |
| TWI548637B (zh) | 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用 | |
| HK40126810A (en) | Polycyclic poly(adp-ribose) polymerase selective inhibitor | |
| CN120829430A (zh) | 三稠环类衍生物抑制剂、其制备方法和应用 | |
| HK1174030B (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
| KR20230014505A (ko) | 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150625 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150902 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150908 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5808408 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |